Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases.

Ivey FD, Wang L, Demirbas D, Allain C, Hoffman CS.

J Biomol Screen. 2008 Jan;13(1):62-71. doi: 10.1177/1087057107312127.

2.

Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.

Ahlström M, Pekkinen M, Huttunen M, Lamberg-Allardt C.

Biochem Pharmacol. 2005 Jan 15;69(2):267-75. Epub 2004 Nov 6.

PMID:
15627479
3.

A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.

Demirbas D, Ceyhan O, Wyman AR, Hoffman CS.

Handb Exp Pharmacol. 2011;(204):135-49. doi: 10.1007/978-3-642-17969-3_5. Review.

4.

Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.

Ahlström M, Pekkinen M, Huttunen M, Lamberg-Allardt C.

Cell Mol Biol Lett. 2005;10(2):305-19.

5.

Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.

Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.

Cell Signal. 2001 Apr;13(4):287-97.

PMID:
11306246
6.

Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.

Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.

Cell Signal. 2001 Mar;13(3):159-67.

PMID:
11282454
7.

Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.

Cherry JA, Thompson BE, Pho V.

Biochim Biophys Acta. 2001 Mar 19;1518(1-2):27-35.

PMID:
11267656
8.

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase.

Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB.

Biochem Biophys Res Commun. 1998 May 29;246(3):570-7.

PMID:
9618252
9.
10.

Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.

Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A.

Clin Cancer Res. 2002 Feb;8(2):589-95.

11.
12.

Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors.

Allen RA, Merriman MW, Perry MJ, Owens RJ.

Biochem Pharmacol. 1999 Jun 15;57(12):1375-82.

PMID:
10353258
13.

Use of a Schizosaccharomyces pombe PKA-repressible reporter to study cGMP metabolising phosphodiesterases.

Demirbas D, Ceyhan O, Wyman AR, Ivey FD, Allain C, Wang L, Sharuk MN, Francis SH, Hoffman CS.

Cell Signal. 2011 Mar;23(3):594-601. doi: 10.1016/j.cellsig.2010.11.013. Epub 2010 Nov 29.

14.

Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.

Pon DJ, Plant M, Tkach J, Boulet L, Muise E, Allen RA, Rodger IW.

Cell Biochem Biophys. 1998;29(1-2):159-78.

PMID:
9631244
15.

The Schizosaccharomyces pombe pde1/cgs2 gene encodes a cyclic AMP phosphodiesterase.

Matviw H, Li J, Young D.

Biochem Biophys Res Commun. 1993 Jul 15;194(1):79-82.

PMID:
8392846
17.

Implications of PDE4 structure on inhibitor selectivity across PDE families.

Ke H.

Int J Impot Res. 2004 Jun;16 Suppl 1:S24-7. Review.

PMID:
15224132
18.

Phosphodiesterase inhibitors in airways disease.

Fan Chung K.

Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. Epub 2006 Feb 2. Review.

PMID:
16458289
Items per page

Supplemental Content

Write to the Help Desk